14
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

DNA alkylation

, , &
Pages 133-136 | Published online: 25 Feb 2005

Reference

  • BOGER DL et al.: Synthesis and properties of substituted CBI analogs of CC-1065 and duocarmycins incorporating the 7-methoxy-1, 2, 9, 9a-tetrahydrocyclopropa-[c]ben[e]indo1-4-one (MCBI) alkylation subunit: magnitude of electronic effects on the functional reactivity. J. Org. Chem. (1996) 61:1710.
  • BARALDI PG et al.: Synthesis, chemical solvolytic stability and preliminary biological evaluation of (±)-N-Boc-CPzI: a pyrazole analog of the left hand segment of the antitumor agent CC-1065. Anticancer Drug Des. (1997) 12:67.
  • BARALDI PG et al.: Synthesis cytotoxicity, antitumor activity and sequence selective binding of two pyrazole analogs structurally related to the antitumor agents U-71, 184 and adozelesin. Anticancer Drug Des. (1997) 12:555.
  • BARALDI PG et al.: Synthesis, solvolytic stability and cytotoxicity of a modified derivative of CPzI, a pyrazole analog of the alkylation subunit of the antitumor agent CC-1065: effect of the nitrogen substitution on the functional reactivity. II Farmaco (1997) 52. (In Press).
  • BARALDI PG et al.: Synthesis, cytotoxicity and antitumor activity of some new simplified pyrazole analogs of the antitumor agent CC-1065. Effect of an hydrophobic group on antitumor activity. II Farmaco (1997) 52. (In Press).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.